Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...

Well-Received Zarxio Will Pave Way to Eventual Wide Biosimilar Adoption

Research Question: Will Sandoz’s (Novartis) Zarxio, the first biosimilar approved by the FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilars? Companies: AMGN, BOM:500359, EPRS, ESRX, HSP, KOSDAQ:068270, NVS, MRK, PFE By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Adoption of […]

Read more...

Biosimilars Whisper

Biosimilars Whisper

Research Question: Will Novartis’ Sandoz Zarxio, the first biosimilar approved by the U.S. FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilar drugs? Companies Covered: Amgen (AMGN), Novartis AG (NVS), Hospera (HSP), Celltrion (068270.KQ), Merck (MRK), Express Scripts (ESRX) Report Available: May 21, 2015   Blueshift’s […]

Read more...

Teva’s Long-Term Success Will Depend on Strategic Acquisitions

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies: ACT, AZN, BIIB, HSP, MYL, NVS, PFE, SLXP, TSE:VRX, TLV:TEVA By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Ten sources who commented offered mixed responses on the likelihood of Teva Pharmaceutical Industries […]

Read more...

Medtronic Whisper

Medtronic Whisper

Research Question: Will Medtronic’s Covidien Solitaire, a neurovascular stent, become the new standard procedure for stroke treatments? Companies Covered: Medtronic (MDT), Stryker (SYK), Johnson and Johnson (JNJ), Boston Scientific (BSX)​ Report Available: April 17, 2015   Blueshift’s initial research shows that the Solitaire neurovascular stent is regarded as a game changer by several medical experts. […]

Read more...

Teva Pharmaceuticals Whisper

Teva Pharmaceuticals Whisper

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies Covered: Teva Pharmaceuticals (TEVA), Novartis AG (NVS), Mylan (MYL) Report Available: March 25, 2015   Blueshift’s initial research shows Teva’s highly profitable MS drug, Copaxone, is nearing the patent cliff, though its patent-protected reformulation of […]

Read more...

Zeltiq’s CoolSculpting System and Treatment Sales Expected to Grow

Research Question: Will Zeltiq continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies: CUTR, ELOS, LMNS, VRX, ZLTQ By: David Franklin Click here to download the report (.pdf)   Summary of Findings Zeltiq Aesthetics Inc.’s (ZLTQ) CoolSculpting procedure is considered the industry-leading noninvasive fat reduction system. CoolSculpting system […]

Read more...

Zeltiq Aesthetics Whisper

Zeltiq Aesthetics Whisper

Research Question: Will ZLTQ continue growing system sales and increasing procedure volume for its CoolSculpting system, or is it a fad? Companies Covered: Zeltiq Aesthetics (ZLTQ), Cynosure (CYNO), Cutera (CUTR), Syneron Medical (ELOS), Lumenis (LMNS), Valeant (VRX) Report Available: February 17, 2015   Blueshift’s initial research shows ZLTQ’s CoolSculpting procedure continuing to rapidly grow in […]

Read more...

Current Exparel Users Satisfied; FDA Concerns Create Potential Hurdles

Research Question: Has the FDA warning letter negatively affected use of Pacira Pharmaceutical’s Exparel? Companies: HCA, HYH, PCRX By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Two distinct schools of thought on the impact of a September FDA warning letter to Pacira Pharmaceuticals Inc. (PCRX) emerged in this report. Industry specialists […]

Read more...